• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

南京诊断吡咯里西啶生物碱所致肝窦阻塞综合征标准的验证

Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome.

作者信息

Zhang Wei, Liu Lu, Zhang Ming, Zhang Feng, Peng Chunyan, Zhang Bin, Chen Jun, Li Lin, He Jian, Xiao Jiangqiang, Feng Yanhong, Wang Xunjiang, Xiong Aizhen, Yang Li, Zou Xiaoping, Yu Yuecheng, Zhuge Yuzheng

机构信息

Department of Gastroenterology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.

Department of Gastroenterology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

出版信息

J Clin Transl Hepatol. 2021 Jun 28;9(3):345-352. doi: 10.14218/JCTH.2020.00124. Epub 2021 Mar 31.

DOI:10.14218/JCTH.2020.00124
PMID:34221920
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8237138/
Abstract

BACKGROUND AND AIMS

Hepatic sinusoidal obstruction syndrome (HSOS) is caused by toxic injury to sinusoidal endothelial cells in the liver. The intake of pyrrolizidine alkaloids (PAs) in some Chinese herbal remedies/plants remains the major etiology for HSOS in China. Recently, new diagnostic criteria for PA-induced HSOS (i.e. PA-HSOS) have been developed; however, the efficacy has not been clinically validated. This study aimed to assess the performance of the Nanjing criteria for PA-HSOS.

METHODS

Data obtained from consecutive patients in multiple hospitals, which included 86 PA-HSOS patients and 327 patients with other liver diseases, were retrospectively analyzed. Then, the diagnostic performance of the Nanjing criteria and simplified Nanjing criteria were evaluated and validated. The study is registered in www.chictr.org.cn (ID: ChiCTR1900020784).

RESULTS

The Nanjing criteria have a sensitivity and specificity of 95.35% and 100%, respectively, while the simplified Nanjing criteria have a sensitivity and specificity of 96.51% and 96.33%, respectively, for the diagnosis of PA-HSOS. Notably, a proportion of patients with Budd-Chiari syndrome (11/49) was misdiagnosed as PA-HSOS on the basis of the simplified Nanjing criteria, and this was mainly due to the overlapping features in the enhanced computed tomography/magnetic resonance imaging examinations. Furthermore, most of these patients (10/11) had occlusion or thrombosis of the hepatic vein, and communicating vessels in the liver were found in 8/11 patients, which were absent in PA-HSOS patients.

CONCLUSIONS

The Nanjing criteria and simplified Nanjing criteria exhibit excellent performance in diagnosing PA-HSOS. Thus, both could be valuable diagnostic tools in clinical practice.

摘要

背景与目的

肝窦阻塞综合征(HSOS)是由肝脏窦状内皮细胞的毒性损伤引起的。一些中草药/植物中吡咯里西啶生物碱(PAs)的摄入仍是中国HSOS的主要病因。最近,已制定了PA诱导的HSOS(即PA-HSOS)的新诊断标准;然而,其有效性尚未经过临床验证。本研究旨在评估PA-HSOS南京标准的性能。

方法

回顾性分析多家医院连续收治患者的数据,其中包括86例PA-HSOS患者和327例其他肝病患者。然后,对南京标准和简化南京标准的诊断性能进行评估和验证。该研究已在www.chictr.org.cn注册(注册号:ChiCTR1900020784)。

结果

南京标准诊断PA-HSOS的敏感性和特异性分别为95.35%和100%,而简化南京标准的敏感性和特异性分别为96.51%和96.33%。值得注意的是,根据简化南京标准,一部分布加综合征患者(11/49)被误诊为PA-HSOS,这主要是由于增强计算机断层扫描/磁共振成像检查中的特征重叠。此外,这些患者中的大多数(10/11)存在肝静脉闭塞或血栓形成,11例患者中有8例发现肝脏有交通血管,而PA-HSOS患者中不存在这种情况。

结论

南京标准和简化南京标准在诊断PA-HSOS方面表现出色。因此,两者都可能是临床实践中有价值的诊断工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d28/8237138/cc5085eaa2dc/JCTH-9-345-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d28/8237138/ce3199cdefd3/JCTH-9-345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d28/8237138/3a74222b2d3c/JCTH-9-345-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d28/8237138/cc5085eaa2dc/JCTH-9-345-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d28/8237138/ce3199cdefd3/JCTH-9-345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d28/8237138/3a74222b2d3c/JCTH-9-345-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d28/8237138/cc5085eaa2dc/JCTH-9-345-g003.jpg

相似文献

1
Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome.南京诊断吡咯里西啶生物碱所致肝窦阻塞综合征标准的验证
J Clin Transl Hepatol. 2021 Jun 28;9(3):345-352. doi: 10.14218/JCTH.2020.00124. Epub 2021 Mar 31.
2
Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.吡咯里西啶生物碱诱导的肝窦阻塞综合征:发病机制、临床表现、诊断、治疗和结局。
World J Gastroenterol. 2019 Jul 28;25(28):3753-3763. doi: 10.3748/wjg.v25.i28.3753.
3
Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi - Case report and literature review.土三七致肝窦阻塞综合征的临床病理特征及诊断——病例报告并文献复习
Open Med (Wars). 2023 Jun 12;18(1):20230737. doi: 10.1515/med-2023-0737. eCollection 2023.
4
Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.吡咯里西啶生物碱诱导的肝窦阻塞综合征的临床特征、CT表现及病理结果:一项回顾性研究
BMC Gastroenterol. 2020 Feb 4;20(1):30. doi: 10.1186/s12876-020-1180-0.
5
Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.吡咯里西啶生物碱诱导的肝窦阻塞综合征临床管理专家共识。
J Gastroenterol Hepatol. 2019 Apr;34(4):634-642. doi: 10.1111/jgh.14612. Epub 2019 Feb 21.
6
Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: five case reports.低分子量肝素治疗吡咯里西啶生物碱所致肝窦阻塞综合征:5例报告
J Int Med Res. 2020 Sep;48(9):300060520961916. doi: 10.1177/0300060520961916.
7
Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.吡咯里西啶生物碱诱导的肝窦阻塞综合征的 CT 增强扫描诊断性能。
Sci Rep. 2016 Nov 29;6:37998. doi: 10.1038/srep37998.
8
Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China.吡咯里西啶生物碱诱导的肝窦阻塞综合征的预后因素:一项中国的多中心研究。
Ann Transl Med. 2021 Jan;9(1):11. doi: 10.21037/atm-20-731.
9
Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.血中吡咯-蛋白质加合物作为吡咯里西啶生物碱致肝窦阻塞综合征的诊断和预后指标
Drug Des Devel Ther. 2015 Aug 25;9:4861-8. doi: 10.2147/DDDT.S87858. eCollection 2015.
10
Tusanqi and hepatic sinusoidal obstruction syndrome.土三七和肝窦阻塞综合征。
J Dig Dis. 2014 Mar;15(3):105-7. doi: 10.1111/1751-2980.12112.

引用本文的文献

1
Serum ascites albumin gradient in predicting the severity of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.血清腹水白蛋白梯度在预测由吡咯里西啶生物碱引起的肝窦阻塞综合征严重程度中的作用
Clin Exp Hepatol. 2025 Jun;11(2):152-159. doi: 10.5114/ceh.2025.151628. Epub 2025 Jun 26.
2
Reduced portal vein blood flow velocity in acute fatty liver of pregnancy.妊娠期急性脂肪肝时门静脉血流速度降低。
Front Med (Lausanne). 2024 Dec 23;11:1506340. doi: 10.3389/fmed.2024.1506340. eCollection 2024.
3
Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives.

本文引用的文献

1
Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.吡咯里西啶生物碱诱导的肝窦阻塞综合征临床管理专家共识。
J Gastroenterol Hepatol. 2019 Apr;34(4):634-642. doi: 10.1111/jgh.14612. Epub 2019 Feb 21.
2
Determination and regulation of hepatotoxic pyrrolizidine alkaloids in food: A critical review of recent research.食品中肝毒性吡咯里西啶生物碱的测定和调控:近期研究的批判性综述。
Food Chem Toxicol. 2018 Sep;119:50-60. doi: 10.1016/j.fct.2018.05.037. Epub 2018 May 14.
3
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
药物性肝窦阻塞综合征:当前进展与未来展望
Arch Toxicol. 2025 Mar;99(3):835-850. doi: 10.1007/s00204-024-03950-9. Epub 2024 Dec 24.
4
Functional metabolomics characterizes the contribution of farnesoid X receptor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.功能代谢组学描绘法尼醇 X 受体在吡咯里西啶生物碱诱导的肝窦阻塞综合征中的作用。
Arch Toxicol. 2024 Aug;98(8):2557-2576. doi: 10.1007/s00204-024-03762-x. Epub 2024 May 4.
5
Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update.中国药物性肝损伤诊治指南:更新版。
Hepatol Int. 2024 Apr;18(2):384-419. doi: 10.1007/s12072-023-10633-7. Epub 2024 Feb 24.
6
Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study.经颈静脉肝内门体分流术治疗由吡咯里西啶生物碱引起的肝窦阻塞综合征:一项多中心回顾性研究
Heliyon. 2023 Dec 8;10(1):e23455. doi: 10.1016/j.heliyon.2023.e23455. eCollection 2024 Jan 15.
7
Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi - Case report and literature review.土三七致肝窦阻塞综合征的临床病理特征及诊断——病例报告并文献复习
Open Med (Wars). 2023 Jun 12;18(1):20230737. doi: 10.1515/med-2023-0737. eCollection 2023.
8
Hepatic Venous Occlusion Type of Budd-Chiari Syndrome versus Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstructive Syndrome: A Multi-Center Retrospective Study.布加综合征的肝静脉闭塞型与吡咯烷生物碱诱导的肝窦阻塞综合征:一项多中心回顾性研究
J Pers Med. 2023 Mar 30;13(4):603. doi: 10.3390/jpm13040603.
9
Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.建立吡咯里西啶生物碱肝窦阻塞综合征鼓室严重程度评分(DTSS)系统。
Hepatol Int. 2022 Jun;16(3):669-679. doi: 10.1007/s12072-021-10293-5. Epub 2022 Jan 12.
10
Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update.1,2-不饱和吡咯里西啶生物碱的代谢解毒导致人类肝窦阻塞综合征:最新进展。
Int J Mol Sci. 2021 Sep 27;22(19):10419. doi: 10.3390/ijms221910419.
欧洲肝脏研究学会失代偿期肝硬化患者管理临床实践指南
J Hepatol. 2018 Aug;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Epub 2018 Apr 10.
4
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease.欧洲肝脏研究学会临床实践指南:酒精性肝病的管理
J Hepatol. 2018 Jul;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018. Epub 2018 Apr 5.
5
Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease.吡咯里西啶生物碱相关肝静脉闭塞病的临床特征和治疗。
Liver Int. 2018 Oct;38(10):1867-1874. doi: 10.1111/liv.13684. Epub 2018 Feb 11.
6
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.EASL 2017 临床实践指南:乙型肝炎病毒感染管理。
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
7
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.EASL 临床实践指南:原发性胆汁性胆管炎患者的诊断和管理。
J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022. Epub 2017 Apr 18.
8
EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure.欧洲肝脏研究学会急性(暴发性)肝衰竭管理临床实践指南。
J Hepatol. 2017 May;66(5):1047-1081. doi: 10.1016/j.jhep.2016.12.003.
9
Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.吡咯里西啶生物碱诱导的肝窦阻塞综合征的 CT 增强扫描诊断性能。
Sci Rep. 2016 Nov 29;6:37998. doi: 10.1038/srep37998.
10
EASL Recommendations on Treatment of Hepatitis C 2016.2016年欧洲肝脏研究学会丙型肝炎治疗指南
J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22.